Media stories about Cleveland BioLabs (NASDAQ:CBLI) have been trending somewhat positive on Tuesday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cleveland BioLabs earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 44.5252073597608 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Separately, ValuEngine downgraded shares of Cleveland BioLabs from a “hold” rating to a “sell” rating in a research note on Friday, December 1st.
Shares of Cleveland BioLabs (CBLI) traded down $0.10 during mid-day trading on Tuesday, hitting $4.04. 15,700 shares of the stock were exchanged, compared to its average volume of 16,760. Cleveland BioLabs has a fifty-two week low of $1.35 and a fifty-two week high of $5.55. The stock has a market cap of $45.22, a P/E ratio of -4.59 and a beta of -0.35.
TRADEMARK VIOLATION NOTICE: “Cleveland BioLabs (CBLI) Given News Impact Score of 0.16” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2018/01/09/cleveland-biolabs-cbli-given-news-impact-score-of-0-16.html.
Cleveland BioLabs Company Profile
Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.
What are top analysts saying about Cleveland BioLabs? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cleveland BioLabs and related companies.